CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

191 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BKRASG12CPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
CKRASG12RPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
BKRASG12SPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BKRASG12APredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAbemaciclibPatnaik et al., 2016
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrametinib,Pemetrexed,DocetaxelGandara et al., 2017
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaNivolumab,AtezolizumabKim et al., 2017
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerSelumetinib,CetuximabDeming et al., 2016
BKRASAmplificationPrognosticSupportsPoor OutcomeEndometrial CancerBirkeland et al., 2012
BKRASG12/G13PrognosticDoes Not SupportPoor OutcomeColorectal CancerSouglakos et al., 2009
BKRASG12/G13PredictiveDoes Not SupportResistanceColorectal CancerOxaliplatinSouglakos et al., 2009
BKRASG12/G13PredictiveDoes Not SupportResistanceColorectal CancerIrinotecanSouglakos et al., 2009
BKRASG12/G13PredictiveDoes Not SupportResistanceColorectal CancerBevacizumabSouglakos et al., 2009
BKRASG12 OR KRAS G13PredictiveSupportsResistanceColorectal CancerCetuximabSouglakos et al., 2009
BKRASG12/G13PredictiveSupportsResistanceColorectal CancerCetuximab,PanitumumabSartore-Bianchi et al., 2009
DKRASG12CPredictiveSupportsSensitivity/ResponseSolid TumorAdagrasibKyriakos P. Papadopoulos, 2019, ASCO Annual Meeting, Abstract TPS3161
DKRASR164QOncogenicDoes Not SupportOncogenicityCancerSmith et al., 2010
DKRASQ61HOncogenicSupportsOncogenicityCancerSmith et al., 2010
DKRASExon 2 MutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerVemurafenibYang et al., 2012
BKRASMutationPredictiveSupportsSensitivity/ResponseOvary Serous AdenocarcinomaBinimetinibMonk et al., 2020
CKRASG12DPredictiveSupportsResistanceLung AdenocarcinomaDabrafenibRudin et al., 2013
BKRASG12CDiagnosticSupportsPositiveLung CancerDogan et al., 2012
CKRASA146VPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAbemaciclibVan Allen et al., 2014
BKRASG13DPredictiveDoes Not SupportResistanceColorectal CancerCetuximabOsumi et al., 2015
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseEndometrial CancerTemsirolimus,RidaforolimusMackay et al., 2014
CKRASG12DPredictiveSupportsSensitivity/ResponsePancreatic CarcinomaAkt Inhibitor MK2206Yap et al., 2011
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerImmunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorRosa et al., 2011
DKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,B-Raf/VEGFR-2 Inhibitor RAF265Lamba et al., 2014
DKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrametinib,AfatinibSun et al., 2014
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerMEK Inhibitor RO4987655Zimmer et al., 2014
CKRASMutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerRefametinibWeekes et al., 2013
CKRASQ22*PredictiveSupportsResistanceColon Mucinous AdenocarcinomaPanitumumabPalmirotta et al., 2009
BKRASG12CPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaDocetaxel,SelumetinibJänne et al., 2015
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrametinibInfante et al., 2012
BKRASAmplificationPredictiveSupportsSensitivity/ResponseSkin MelanomaSorafenib,Carboplatin,DocetaxelWilson et al., 2016
CKRASG12DPredictiveSupportsResistanceHairy Cell LeukemiaVemurafenibTiacci et al., 2015
BKRASMutationPredictiveSupportsSensitivity/ResponseHepatocellular CarcinomaSorafenib,RefametinibLim et al., 2014
CKRASG12VPredictiveDoes Not SupportResistanceCancerCrizotinibPalma et al., 2014
BKRASG12APredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
BKRASG12APredictiveSupportsResistanceMultiple MyelomaMelphalanGreco et al., 2009
DKRASG12APredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2000
DKRASG12APredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2002
DKRASG12APredictiveSupportsResistanceMultiple MyelomaMelphalanHoang et al., 2006
DKRASG13DPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,DactolisibMigliardi et al., 2012
DKRASG12CPredictiveSupportsSensitivity/ResponseColorectal CancerSelumetinib,DactolisibMigliardi et al., 2012
BKRASG12DPredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
BKRASMutationPredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinibRamalingam et al., 2011
DKRASG12DPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2000
DKRASG12DPredictiveSupportsResistanceMultiple MyelomaMelphalanHoang et al., 2006
BKRASG12CPredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
Page 3 of 4
PreviousNext